All Projects

Our cofounders have over 78 years of healthcare and decades of strategy consulting experience completing hundreds of engagements.

Completed Projects:
  • Global Assessment of Pre-Launch Communication Strategies for COX-II Inhibitors
  • Launch Strategy for a Long-Acting Insulin
  • Patent Expiration of an Anti-Psychotic
  • An In-Depth Assessment of a Company's Alpha1-Proteinase Inhibitor
  • Assessment of a Company and Its COX-2 Franchise
  • Competitors to a Branded Schedule -II Narcotic Analgesic
  • Evaluation of a Company's Strategy to Introduce an Abuse Deterrent C-II Narcotic Medication
  • Competitive Assessment of CNS Products
  • Assessment of Multicultural Consumer Marketing Activities
  • Clinical Program of Two Key Competitors to an Atypical Antipsychotic
  • Competitive Analysis of an IV COX-II Inhibitor and Their Portfolio Strategy
  • Analysis of a Company's Launch Strategy for a Beta-2 Agonist
  • Issues Facing a Company's Anti-infectives franchise
  • Levothyroxine Sodium Franchise Generic Monitoring
  • Evaluation of a Company's Strategy to Introduce an Abuse Deterrent C-II Narcotic Medication
  • Generic Cholinesterase Inhibitor Monitoring
  • Competitive Landscape Monitoring of the Narcotic Analgesic Market
  • CI Program for A Branded Atypical Antipsychotic
  • CI Landscape Overview of Asthma Therapies
  • ICAAC Meeting Coverage
  • Alcohol Abuse/Drug Abuse Treatments in Development
  • Monitoring Program Assessing Potential Threats to Two Tretinoins
  • Inhalable Asthma Products
  • Landscape Analysis of the Osteoporosis Market
  • A Wholesaler's Strategy in Pharmacy Management
  • Branded and Generic Monitoring for a Hyperlipidemia Franchise
  • Evaluation of a Clinical Program for a PDE-IV Inhibitor for Asthma
  • Comprehensive Monitoring of the U.S. Insomnia and Sleep Market
  • Assessment of the Quinolone Antibiotic Marketplace
  • Landscape Overview of VLA4 Agents, Development Plans and Target Indications
  • Competitive Landscape Assessment of the Generalized Anxiety Disorder Markets
  • PDE-IV Landscape Overview For Asthma and COPD
  • Albuterol HFA Launch Strategy Assessment
  • Anti-TNF Manufacturing Capacity and Related Issues
  • Competitive Assessment of a Modified-Release Non-Benzodiazepine Agonist
  • Levothyroxine Sodium monitoring
  • Monitoring of Potential Threats to Two Tretinoins
  • Detailed Competitive Assessment of Selected Vaccines Possibly Being Developed by Company X
  • Products in Development for the Treatment of Eating Disorders
  • Detailed Assessment of Potential Competitive Threats to a Company's Hyperlipidemia Franchise
  • Deep Dive Competitive Assessment of the Clinical Trial Design and Development Program of a Oral Smoking Cessation Agent
  • Assessment of Emerging and Established Competitors in Pain Management
  • Deep Dive Assessment of Two Drugs in Development for Anxiety
  • Company A's Strategy and Tactics for the Promotion of a Epilepsy Drug for PHN
  • Assessment of Potential Competitors to the Product a Patch in Canada
  • Assessment of Competitors to a Cholinesterase Inhibitor in MCI
  • Targeted Monitoring of Two Companies' Prescription Drug Programs
  • Detailed Assessment of Two Triptans
  • Levothyroxine Sodium Franchise Generic Monitoring
  • Assessment of A Company's Agent for Generalized Anxiety Disorder
  • Monitoring for Competitors to a Levothyroxine Sodium Brand
  • Potential Competitive Threats to a Hyperlipidemia Agent
  • Assessment of Competitors to an Oral C-II Lozenge
  • Assessment of Apoptosis Agents in Oncology
  • Assessment of Generic Threats to an Organ Transplant Rejection Product
  • Assessment of the U.S. Strategy for a Viscosupplement
  • Assessment of Company A's Future Anti-Emetic Strategy
  • Assessment and Monitoring of Competitors to a C-II Narcotic Patch
  • Detailed Competitive Assessment of Potential Generic Threats to A Company's Oncology Brand
  • Generic Competitors to a Sustained-Release C-II ADHD Medication
  • Assessment of the Coxib Marketplace
  • Assessment of Potential Generic Competitors to a Long-Acting Oral C-II Narcotic
  • Generic Threats to an Oral Progesterone Monitoring Program
  • Competitive Assessment of the Levothyroxine Sodium Market
  • Assessment of Generic Threats to a Scheduled Oral Anti-Emetic
  • Assessment of New Long-Acting Bronchodilator Formulations
  • Company A's Sales/Marketing to Support an Oral Phosphate Lowering Agent in Top 5 EU countries
  • Assessment of Competitors with Generic X (Anti-Emetic)
  • Generic Levothyroxine Sodium Pre-submissions
  • Update on TRAIL Ligand Project
  • Monitoring Competitors to a Leading Brand Insomnia Drug
  • Competitive Monitoring to Support an Epileptic/Bipolar Franchise
  • Metabolic Group Retainer - Levothyroxine Sodium
  • Follow-up Assessment of Substance Abuse Products
  • Parts II and III of the Follow-up Assessment of Substance Abuse Products
  • Assessment of a PDE-IV Inhibitor
  • Assessment of the lifecycle management of Company A's C-II Narcotic Analgesic Patch and Generic Entrants
  • An Assessment of the Branded and Generic Anesthetic Product Market
  • Focused Assessment of Key Issues Regarding the Impending Launch of a Fixed-Dose Thiazolidinediones and Sulfonylurea
  • Organ Transplant Rejection Generic Threat Assessment Monitoring
  • Smoking Cessation Agent Landscape Overview
  • Assessment of Select Competitors in Alzheimer's Disease
  • Scientific and Commercial Evaluations of A 5HT3 Antagonist and an Interferon
  • Identification and Assessment of Competitor's Plans to Develop a Modified-Release Version of a Hard to Make Seizure Medication
  • Monitoring of Competitors to a Leading Insomnia Franchise
  • Reformulations of Topiramate and Pramipexole
  • Levothyroxine Sodium Monitoring
  • Assessment of Competitors to A Product's C-II Narcotic Lozenge
  • Retainer Program for an Epileptic/Bipolar Agent Franchise
  • Assessment of Manufacturing Issues at Company A
  • Alzheimer's Landscape Assessment
  • NSAID Patch Competitors
  • Assessment of Competitors in Viscosupplements
  • Authorized Generic for Company A's Oral Long-Acting Narcotic Analgesic
  • Anti-Emetic Assessment
  • CNS Insomnia Project Supplemental Retainer
  • Parkinson's Landscape Assessment
  • An Overview and Assessment of the Launch of A Viscosupplement
  • Generic Product Assessment
  • Retainer Hours - Epilepsy Drug/Bipolar Drug franchise
  • Retainer Hours - CNS Program
  • Alzheimer's Competitive Monitoring
  • Epilepsy Drug/Bipolar Drug Franchise Monitoring (Meeting Coverage)
  • Epilepsy Drug/Bipolar Drug Franchise Monitoring (Retainer Hours)
  • Competitive Intelligence Proposal to Support an Oral Dopamine Agonist Franchise at the World Parkinson Congress
  • CI Retainer for an Oral Bisphosphonate Franchise
  • Targeted Monitoring of an Oral Protease Inhibitor for HCV
  • mGluR Competitive Landscape
  • Psychiatry Meeting Coverage
  • Monitoring for Hep C Competitors
  • Clinical Trials Assessment of Transdermal Anesthetic Patches in Development
  • Sales and Marketing Strategies of Select Competitors in CINV
  • Targeted Assessment of an Oral Novel Antipsychotic
  • Pain Management/Anti-inflammatories & Analgesics
  • HCV Monitoring of an Oral Protease Inhibitor
  • Levothyroxine Sodium Monitoring
  • Go/No Go Decision to Pursue an Indication for Alcoholism
  • Continuation of Epilepsy/Bipolar Monitoring - Ad-Hoc
  • CNS Monitoring
  • Clinical Assessment of Oral HCV Protease Inhibitor
  • Generic Competitors to an Oral Proton Pump Inhibitor in Canada
  • Consulting in the CNS Space
  • Comprehensive Competitive Intelligence Monitoring Program Supporting the Neuroscience Team
  • Landscape Assessment for A Leading Brand Team in Schizophrenia
  • Competitive Intelligence Coverage of the American Psychiatric Association
  • Assessment of Specific Competitors in the Opioid Market
  • Identification of Compounds in Development for Neuropathic Pain (Phase II & III)
  • Competitive Landscape Assessment of New Formulations in the Pain Market
  • Comprehensive Quarterly Monitoring Program to Support Company X's ’ Alzheimer’s Franchise
  • Launch Plan in Pain Market
  • A Company's Plans to Introduce Acne Products with Benzoyl Peroxide
  • Unmet Needs in Acute Pain
  • Landscape/Monitoring of Antipsychotics
  • Insomnia Market Coverage
  • Assessment of Potential Generic entrants for a FDC Oral Products for Asthma/COPD
  • Bipolar/Epilepsy Monitoring
  • Type 2 Diabetes Market - Conference Coverage
  • Anesthesia Market Competitive Intelligence
  • Comprehensive Assessment of Select Competitors’ Organizational Strategies and Structures
  • HepC Monitoring
  • Third-party assessment of pipeline products
  • Insomnia Monitoring
  • Bipolar Depression/Schizophrenia Monitoring
  • Depression monitoring
  • Generic Cholinesterase Inhibitor in Canada
  • Anti-Depressant Launch Tracking
  • Comprehensive Managed Care Contracting Strategy Assessment Across Eight Peer Companies
  • A Retainer Agreement for Investigating Market Events in the Atypical Antipsychotic Marketplace
  • Insomnia in Big 5 EU Markets
  • Snapshot Assessment of Potential Generic Entrants to an Intranasal Migraine Medication
  • Launch Evaluation
  • LTC Strategy
  • Insomnia Market Coverage
  • Assessment of 5 competitive products in Alzheimer’s Disease
  • Multicultural Marketing
  • Comprehensive Yearly Monitoring and Retainer Program to Support Company A's Alzheimer’s Franchise
  • Competitive Intelligence Retainer Program (Retainer Hours) - Levothyroxine Sodium Market
  • EU Insomnia
  • Bipolar/Epilepsy Retainer Renewal
  • EU Smoking Cessation
  • A Competitive Intelligence Proposal To Support A Company in Multiple Sclerosis
  • CI Outsourcing Initiative
  • AASLD and HEPDART Conference Coverage
  • Competitive Intelligence Retainer Agreement (Anesthesia)
  • Hep C Monitoring
  • Monthly Newsletters - Intranasal Migraine Drug Franchise
  • Assessment of Competitive Threats to a Branded Atypical Antipsychotic
  • Global Monitoring Program for A PPI/NSAID Combination Product
  • ECNP Congress Coverage
  • Support for US PPI/NSAID Team
  • Company A ADHD Launch Evaluation
  • Assessment of Competitive Products in Alzheimer’s Disease
  • Osteoarthritis KOL Database
  • Additional 50 Retainer Hours
  • Competitive Assessment of Pain market
  • Anti-TNF Manufacturing Costs and Capacity
  • Assessment of a New Novel Atypical Antipsychotic
  • Large Pharma Company Strategy Marketing Assessment
  • Patch Company Assessment
  • Parkinson’s Disease Landscape Including DBS
  • Oncology (Global)
  • Generic Threats to An ODT and XR Anti-Epilepsy Drug
  • Intranasal Migraine Brand Team Monthly Newsletters
  • Assessment of Decision Influences for Prescription of Target Pain Management Products
  • Assessment of Competitive Products in Alzheimer’s Disease
  • Oral Anti-Epileptic and Organ Transplant Rejection Medication Project
  • Ad Hoc Retainer - Anesthetic Franchise
  • Assessment of Patents and Products in the Anti-emetic Markets
  • Competitive Neurotoxin Profiles
  • Multiple Sclerosis Monitoring
  • Landscape/Monitoring of Antipsychotics
  • Anesthesia Market Competitive Intelligence
  • Alzheimer's Monitoring
  • Insomnia Market Coverage
  • Insomnia in Big 5 EU Markets
  • An Assessment of Select Competitors to An Aesthetic Company
  • Monitoring of generic competitors to An Oral Scheduled Anti-Emetic
  • Insomnia Monitoring
  • Depression Monitoring
  • CNS-Depression/Fibromyalgia, and Insomnia
  • CNS-Insomnia
  • Inhaled Osteoporosis Medication
  • MC Sales Force Strategy
  • Project Macbeth -Insomnia Drug
  • Assessment of the 5HT3 Anti-Emetic Market
  • Landscape Overview of the Binge Eating Disorder Market
  • Competitive Threat Assessment of Products for Overactive Bladder
  • Launch Excellence Project to Support a Transdermal Antidepressant
  • Organizational Benchmarking of a Large Company's Managed Care Team
  • Leading Brand Antipsychotic Monitoring
  • Leading Brand Monitoring
  • IDN and Payer Strategy Assessment
  • Support for PPI/NSAID Combination Franchise
  • Snapshot Assessment of Competitive Threats in Prostate Cancer
  • Competitive Landscape for Products in Development for Treatment Resistant Depression
  • Scheduled Narcotic Analgesic Monitoring
  • Pneumococcal vaccines
  • Coverage of ASHP
  • Landscape Overview of the Opioid Induced Constipation Market
  • Scheduled Narcotic Analgesic Monitoring
  • Multiple Sclerosis Monitoring
  • Landscape Overview of the Neuroprotection Market
  • Overview of the Testosterone Replacement Market
  • Parkinson's Landscape Assessment Including DBS
  • Narcotic Analgesic State Board of Pharmacy State Inspector Advocacy
  • ASHP and APIC Coverage
  • Overview of the Viscosupplement Market
  • Ad Hoc to Support Mature Brands
  • Pneumococcal vaccines
  • Scheduled Narcotic Analgesic Monitoring
  • ASHP Coverage
  • Sleep Landscape Monitoring with Focus on Sleep-Wake Cycle Agents
  • Ad Hoc Assistance in the Pain and Opioid Induced Constipation Market
  • Abuse Deterrent Landscape
  • Pneumococcal Vaccines
  • Launch of an Oral Antibiotic by Company A
  • IL-17 Launch Assessment
  • HIMSS Healthcare IT Assessment
  • Alcohol Dependency
  • AAPM Coverage
  • EFIC Conference
  • Ad Hoc Project
  • GI Product and Technology Landscape Assessment
  • Global Competition in AD and PD
  • Competitive Monitoring for a Novel Oral Anticoagulant
  • ECNP Coverage
  • Gastrointestinal OTC Assessment
  • Deep Brain Stimulation Monitoring Business for a Parkinson's Disease Product
  • Assessment of a Hyperkalemia Drug in the U.S.
  • Heart Failure Monitoring
  • HCV Managed Care
  • U.S. Competitive Monitoring Program for Select Antibiotics
  • PCSK-9 Competitive Monitoring for Hyperlipidemia Market
  • Infectious Disease Ad Hoc
  • Epilepsy Monitoring
  • Oral Anti-Fungal Project Assessment
  • ASCO Coverage
  • Facial Aesthetics
  • Medical Toxins
  • Epilepsy Monitoring
  • Immunoglobulin G Products
  • American College of Rheumatology Coverage
  • Competitor Launch Strategy in the Moderate-Severe Asthma Space
  • Schedule -II Narcotic Analgesic Monitoring
  • Pricing of Oncology Drug Antidote
  • Multiple Sclerosis Contracting
  • Neuroprotection
  • Organizational Benchmarking
  • Traumatic Brain Injury Monitoring
  • CNS Monitoring of the Epilepsy Market
  • HCV Monitoring
  • CROI Conference Coverage
  • Competitive Analysis of Contracting in Immunology
  • Hyaluronic Acid Monitoring
  • Levothyroxine Sodium Market Ad Hoc Retainer
  • Heroin Addiction Landscape
  • Antibiotic Monitoring
  • Botulinum Toxin Therapeutic Market Competitive Landscape
  • Cutaneous T-Cell Lymphoma Monitoring
  • Assessment of Four CNS Pipeline Opportunities
  • Conference Coverage
  • Dyslipidemia Monitoring
  • Immunology
  • Retrospective Sales Force Assessment
  • Oncology Agent Commercial Monitoring
  • IASP Conference Coverage
  • Pancreatic Cancer
  • Mature Brands
  • Schedule-II Narcotic Analgesic Market Monitoring
  • RX/OTC Strategies
  • Deep Brain Stimulation
  • Pain Market Ad Hoc
  • Global HCV
  • HCV Managed Care
  • Global Surveillance of Generic Developments, Including Potassium Chloride, A First- Generation Antipsychotic, Muscle Relaxer, and Pain Patch
  • European Suboxone generics monitoring
  • Global Pain Monitoring
  • U.S. Facial Aesthetics
  • Obesity Managed Care
  • Competitor Surveillance and Conference Coverage Program in the Epilepsy Therapy Area
  • ASCO Coverage
  • AES Coverage
  • 100 Hours of Ad Hoc
  • Pancreatic Enzyme Replacement Market Monitoring
  • In-Depth Assessment of Medical Science Liaison Characteristics
  • Novel Oral Anti-coagulant Monitoring
  • Ad Hoc Pain Managed Care
  • Pain Monitoring
  • Consumable Competitor Activity
  • HCV Managed Care Monitoring
  • U.S. MS Monitoring
  • EU MS Monitoring
  • Healthcare IT Platforms
  • Assessment of Generic Threats to an OTC PPI
  • Competitive Intelligence Retainer to Address Food Allergy Competitors
  • Breast Cancer Monitoring
  • OTC Regulatory CI Project
  • Global Commercial Monitoring in Support of a Novel Oral Anti-Coagulant
  • HCC (1st-line/2nd-line)
  • Food Allergy Competitive Monitoring
  • Pump Monitoring Assessment
  • APA and ASCP Coverage
  • Pancreatic Cancer
  • Immunology Conference Coverage
  • Anti-platelet Quick Dive
  • Additional Coverage at AAN and ECTRIMS
  • CGRP Managed Care Competitive Intelligence
  • PAH Monitoring
  • ERS Coverage
  • 50 Ad Hoc Hours
  • HCV Monitoring
  • Ad Hoc Rare Blood Disease
  • Arab Health Conference
  • Commercial Valuation for a Novel Non-Opioid IV Pain Medication in in Acute-Post operative and Neuropathic Pain Indications
  • Managed Care in Three Therapy Areas
  • Managed Care
  • Pump Monitoring Assessment
  • Food Allergy Competitive Monitoring
  • Prescription Drug Patient Assistance Programs
  • U.S. Aesthetics
  • ASCO Coverage
  • Insomnia U.S.
  • Insomnia secondary
  • Insomnia ex-U.S.
  • Lupus Asset Valuation
  • Managed Care Monitoring
  • ASCO Coverage
  • AAN Coverage
  • AHS Coverage
  • Rheumatology Monitoring
  • Women’s Health Monitoring
  • Pricing Assessment Erythropoetin Products